Test KB407 inhaled treatment for adults with cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This Phase 1 study tests the safety of KB407 and how it works in adults with cystic fibrosis (CF). It may help researchers understand whether this inhaled treatment could become a future option for CF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older) and can sign consent and follow study steps
- You have confirmed cystic fibrosis (CF) based on CF findings and genetic/sweat test results
- Your lung function is in a moderate range (FEV1 predicted between 40% and 90%)
- You have good breathing oxygen levels (at least 92% oxygen saturation on room air)
- You have not started any new long-term CF medicines or changed them within 28 days before the first dose
- You are not pregnant or nursing, and you can follow required birth-control rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
This trial tests a new inhaled medicine (BMD003) that delivers CFTR mRNA to help correct the genetic defect causing cystic fibrosis. It is for patients who are 12 years or older, have stable CF, and meet certain lung function and weight criteria.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.